Intravitreal administration of angiogenesis inhibitor in the treatment of age-related macular degeneration of the retina
https://doi.org/10.34215/1609-1175-2020-3-83-85
Abstract
Summary: Age related macular degeneration of the retina is a leading cause of severe loss of central vision among elderly people. The introduction into clinical practice of inhibitors of vascular endothelial growth factor has become an important milestone in the treatment of this disease. The article demonstrates three cases of aflibercept (Eylea) application in elderly patients with wet age-related macular degeneration. The medication has demonstrates a high clinical efficacy. Further obser‑ vation is required to assess long-term results.
About the Authors
O. V. Miroshnichenko
Far Eastern Federal University
Russian Federation
Russian Federation
MD, PhD, Medical Center,
10 Ajax Bay, Russky Island, Vladivostok, 690922
N. G. Shramko
Far Eastern Federal University
Russian Federation
Russian Federation
MD, Medical Center,
10 Ajax Bay, Russky Island, Vladivostok, 690922
O. I. Pak
Far Eastern Federal University
Russian Federation
Russian Federation
MD, PhD, Medical Center,
10 Ajax Bay, Russky Island, Vladivostok, 690922
E. O. Yatsenko
Far Eastern Federal University
Russian Federation
Russian Federation
MD, Medical Center,
10 Ajax Bay, Russky Island, Vladivostok, 690922
N. V. Filina
Pacific State Medical University
Russian Federation
Russian Federation
MD, PhD, associate professor,
2 Ostryakova Ave., Vladivostok, 690002
D. A. Hvan
Vladivostok Polyclinic No. 9
Russian Federation
Russian Federation
MD,
3 Admiral Gorshkov St., Vladivostok, 690105
References
1. Alpatov SA. Angiogenesis blockers in the treatment of eye diseases. RMJ. Clinical Ophthalmology. 2015;15(1):32–7 (In Russ).
2. Izmailov AS, Balashevich LI. Choroidal neovascularization. Epidemiology, pathogenesis, clinic. Ophthalmosurgery and Therapy. 2004;3(4):38–46 (In Russ).
3. Kudyavtseva YuV, Demakova LV, Podyninogina VV, Patrusheva IN, Smerdova EN. Experience with the use of the drug aflibercept in the treatment of neovascular eye diseases of various origins. Modern Technologies in Ophthalmology. 2019;1:105–8 (In Russ).
4. Rakic J-M, Lambert V, Devy L, Luttin A, Carmeliet P, Claes C, et al. Placentalgrowth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(7):3186–93.
5. Fedyanin MYu. Aflibercept: Focus on side effects. Medical Advice. 2018;10:18–26 (In Russ).
6. Nevskaya AA, Korol AR. A case of treatment of a patient with transudative detachment of retinal pigment epithelium with age-related macular degeneration. Ophthalmological Journal. 2014;52(6):128–31 (In Russ).
7. Tereshchenko AV, Bely YuA, Kovalevskaya MA, Milyutkina SO. On the issue of evaluating the effectiveness of anti-VEGF-therapy of macular edema in AMD. Ophthalmosurgery. 2014;4:95–100 (In Russ).
8. Horoshih YuI, Krivoshein OI. Modern views on the problem of pathogenesis and treatment of the “wet” form of age-related macular degeneration. Modern Problems of Science and Education. 2014;2:350 (In Russ).
9. Budzinskaya MV, Plyukhova AA, Shelonkova AV, Kuznetsov AV, Andreeva IV. Comparison of clinical and Real-life studies of the effectiveness of anti-VEGF therapy for age-related macular degeneration. Siberian Scientific Medical Journal. 2018;5:102–5 (In Russ).
10. Gosudarstvennyj reestr lekarstvennyh sredstv (In Russ). URL: https://grls. rosminzdrav.ru (Accessed June 11, 2018).
11. Rudge JS, Holash J, Hylton D, Russel M, Jiang S, Leidich R, et al. VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci. 2007; 104(47):18363–70.
12. Likhova EA, Kovalchuk DYu, Ponomarenko DM, Shevchuk AV. Clinical experience with the use of the drug aflibercept in the second line of therapy for metastatic colorectal cancer. Effective Pharmacotherapy. Oncology, Hematology and Radiology. 2017;2(20):38–40 (In Russ).
13. Beykin G, Grunin M, Averbukh E, Banin E, Hemo Y, Chowers I. Bevacizumab treatment for neovascular age – related macular degeneration in the setting of a clinic: “real life” long-term outcome. BMC Ophthalmol. 2015;15:39. doi: 10.1186/s12886-015-0019-x
14. Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11):844–51.
15. Bobykin EV. Anti-angiogenic therapy for treatment of macular disorders in ophthalmology. Literature review. Practical Medicine. 2018;5:104–11 (In Russ).
Review
For citations:
Miroshnichenko O.V., Shramko N.G., Pak O.I., Yatsenko E.O., Filina N.V., Hvan D.A. Intravitreal administration of angiogenesis inhibitor in the treatment of age-related macular degeneration of the retina. Pacific Medical Journal. 2020;(3):83-85. (In Russ.) https://doi.org/10.34215/1609-1175-2020-3-83-85
Views:
530
Email this article 